PRM36 Patient-Reported Outcome and Quality of Life Instruments Database (PROQOLID): Evolution of Content, Structure, and Functionalities (2002-2012)  by Emery, M.P. et al.
several sources of real world data available to researchers.METHODS:We compare
and contrast the pros and cons of data available from administrative (payment)
databases, electronic medical record (EMR) databases, and surveys. RESULTS: Ad-
ministrative claims databases provide fully-integrated, all-encounter patient data
on diagnoses, procedures, and payments. However, data quality varies depending
upon whether particular fields are required for provider payment. Data on lab and
test values are typically lacking. Prescriptions that are written, but not filled by the
patient, are usually not captured. Medical record data overlap, to a certain extent,
with administrative data. While information on payments for services may not be
included, detailed information on test results and lab values are usually captured
in the EMR. Data are included on written prescriptions, but the researcher will not
know whether the prescription was filled by the patient. Depending upon the clin-
ical system covered, only some encounters (e.g., ambulatory care in the outpatient
setting) may be available. Both administrative and EMR data hold the potential to
provide longitudinal patient information that is not subject to recall or social de-
sirability biases that often affect survey data. However, information on satisfaction
with care, quality of life, activities of daily living, and many other metrics, may only
be captured with survey data. CONCLUSIONS: Several sources of rich, longitudinal
patient data are available to provide real world evidence on drug effectiveness and
cost. In some cases, data may be combined to overcome limitations of a single
source. With care, data may be found that will produce generalizable findings for
the population of interest.
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OBJECTIVES: Gathering data tends to be an expensive and time consuming task.
During the IFEDH research project different methods for using routine data on
models in HTA were discussed, improved and developed. Connecting a rich dataset
from Austrias inpatient sector lacking patient identifiers and (kind of) personalized
but sparse records from the outpatient sector provided by different social security
institutions is the objective of this project. A detailed description of the setup and
usage of the results were presented at the SHIP Conference 2011 in St. Andrews
(http://www.scot-ship.ac.uk/conference-2011) and the International Data Linkage
Conference 2012 in Perth (http://www.datalinkage2012.com.au/). METHODS: Doc-
umentation of prior processing and information of the provided data were not fully
available and also questionable data quality and the presence of possible dupli-
cates result in technical and contextual challenges. After prepossessing, data qual-
ity assessment and other preparations, a deterministic record linkage approach
was developed using a combination of the open and freely available statistical
environment R and PostgreSQL database. Based on dynamically created SQL state-
ments and extensive logging, the linkage process can be enhanced easily if new
knowledge about the input data gets available. RESULTS: The resulting linked
dataset provides high quality and immediately available information. Additionally
the deterministic linkage process can be examined and understood by its users.
Therefore linkage and data errors are identified easily and feedback can be used to
enhance the overall result. These experiences also lay the foundation for more
advanced linkage methods and further improvements. CONCLUSIONS: After the
long and challenging way from the first data import to a functioning data collec-
tion, adequate information can now be used in different projects with low costs
and users confidence.
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OBJECTIVES:With introduction of AMNOG legislation, the pharmaceutical compa-
nies must submit a dossier when launching new drugs. The dossier must include
an estimate of number of patients to be treated. This is particularly challenging in
case of rare diseases, as shown with transthyretin-type familial amyloid polyneu-
ropathy (TTR-FAP). METHODS: Several sources were used for a comprehensive
gathering of information. Apart from systematic literature research, incidence data
was searched by internet research and within patient registers. Since current ther-
apy of choice is liver transplantation, the German Organ Transplantation Founda-
tion was consulted regarding frequency of liver transplantation in connection with
TTR-FAP. Assuming all patients are immediately placed on a waiting list after
diagnosis, the number of annually performed surgeries was equaled with the inci-
dence of the TTR-FAP. Results of this research were compared to billing data of a
national statutory health insurance. RESULTS: Given its European prevalence of
approx. 1.1/100,000, TTR-FAP is an ultra-orphan-disease. For endemic regions
(Sweden, Portugal) the disease is well captured and documented. For Germany, no
comparable published data is available. 5 national treatment centers were identi-
fied that document their patients in various registers, reflecting an incidence of
about 7 surgeries per year. According to the German Organ Transplantation Foun-
dation on average 6 new TTR-FAP patients per annum were added to the waiting
list, confirming the estimate of the incidence derived from registers. Domino trans-
plantation is usual in TTR-FAP with an average of 6.5 domino transplantations p.a.,
validating the estimate of an incidence of 6 – 7 patients per year. Billing data reflects
an estimated prevalence between 0.6 and 1.4/100,000. CONCLUSIONS: Data on the
prevalence of rare diseases frequently is not available or very unreliable. Different
sources produce strongly varying results due to several reasons. This must be taken
into account when assessing the number of patients in the value dossiers for new
drugs.
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OBJECTIVES: PROQOLID was developed in 2002 to provide all those involved in
health care evaluation with a comprehensive and unique source of information on
Patient-Reported Outcome (PRO) and Health-Related Quality of Life (HRQL) mea-
sures available through the Internet. The objective of this study is to review the
evolution of content, structure, and functionalities of PROQOLID since 2002.
METHODS: The archives of PROQOLID were searched to retrieve the database just
before its launch and to compare its content and structure as it was in April 2012.
RESULTS: The first database, then known as QOLID, was retrieved. It included 313
instruments (32 generic and 281 disease- or condition-specific). Instruments spe-
cific to oncology were the most frequent (54). The structure had three categories:
contact, conditions of use, and a copy of the questionnaire. By comparison, the
April 2012 database includes 714 instruments (128% increase, with 100 generic and
614 specific), with an increase of almost 40 instruments each year (up by 401 in 10
1/2 years). Instruments specific to nervous system diseases are the most frequent
(141), reflecting the evolution in the field (e.g., 76.7% of the neurological products
authorized by the EMA have been approved since 2002). The information displayed
for each instrument has been improved with the addition of five categories: trans-
lations available, descriptive information, content validity documentation, mea-
surement properties, references, and websites. In January 2005 the database was
renamed PROQOLID to reflect the wider use of the term PRO. In April 2012, a new
Google-type search engine was added to make browsing more user friendly. Soon
all users will have more information about instruments distributed by MAPI Re-
search Trust. CONCLUSIONS: In just over 10 years, the PROQOLID database has
considerably evolved in content and structure, and offers a range of information
and services adapted to the evolution of the field.
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OBJECTIVES: As part of consulting projects IMSCG performs 5000 payer inter-
views p.a. Interview analysis is typically focused on insights directly related to
research objectives. However, often respondents provide perceptions/ un-
prompted insights unrelated to research objectives, which have never been anal-
ysed before. The objective was to test whether information obtained from un-
prompted payer responses in interview write-ups can be identified and analysed,
to develop insights of payer perceptions of pharma and their impact on payer
decisions. METHODS: We selected 100 projects performed 2008-2011 including
double blinded interviews with national/regional payers/advisors, recorded in Eng-
lish in the IMSCG project database. Interviews were screened for quotes reflecting
perceptions of pharma unrelated to the research objective. Only unprompted ex-
pressions were extracted and buzz-words created that allowed compression into a
single word/phrase. Buzz-words were valued and categorized into perception clus-
ters (reputation, interaction, employees, portfolio and research) to identify the
cause of perceptions. Quotes linking perceptions directly to decisions were
mapped separately. Respondents’ function and geography were interlinked with
the information. RESULTS: We identified 543 interviews including 900 quotes with
unprompted expressions of perceptions in 1900 buzz-words. Distribution of inter-
views was equal between national/regional payers, but 80% of quotes came from
regional payers. Top5 EU accounted for majority of quotes. Company specific and
industry perceptions were evenly split. Data allows a variety of perception analysis:
national vs. regional payer, pharma vs. company, company perceptions of national
vs. regional payers. Perception clusters identify the cause of perceptions. Analysis
of the impact of perception on payer decisions is feasible, based on 5% of overall
quotes. CONCLUSIONS: The data allows a structured analysis of unprompted ex-
pressions of payer perceptions in retrospective research. Database processing is
ongoing to derive in the future statistically significant answers related to the im-
pact of payer perceptions on decisions and what these perceptions are based upon.
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